Pediatric Cancer Biomarker Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025

Description

Persistence Market Research has recently released a comprehensive report on the global Pediatric Cancer Biomarkers Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

Pediatric Cancer Biomarkers Market Size (2025E): US$ 909.6 Mn
Projected Market Value (2032F): US$ 1,642.4 Mn
Global Market Growth Rate (CAGR 2025 to 2032): 8.8%

Pediatric Cancer Biomarkers Market - Report Scope:

The pediatric cancer biomarkers market encompasses a wide range of biological markers used for early detection, diagnosis, prognosis, and therapeutic response prediction in pediatric oncology. These biomarkers, including proteins, gene mutations, and circulating tumor DNA, are critical in managing childhood cancers such as leukemia, neuroblastoma, and central nervous system (CNS) tumors. Technological advancements in genomic and proteomic profiling, rising cancer incidence among children, and the growing emphasis on personalized medicine are fueling the adoption of pediatric cancer biomarkers. Improved diagnostic accuracy and the availability of non-invasive testing methods are further propelling market growth.

Market Growth Drivers:

The global pediatric cancer biomarkers market is being driven by a surge in cancer incidence among children and a growing focus on early and accurate diagnostics. The increasing adoption of precision medicine and the development of novel biomarker-based diagnostic tools are accelerating the demand for advanced cancer detection methods. Technological innovations in next-generation sequencing (NGS), liquid biopsy, and molecular diagnostics are further enhancing the reliability and efficiency of biomarker testing. Supportive government initiatives and rising investments in pediatric oncology research are also playing a crucial role in expanding market opportunities. The trend toward non-invasive diagnostic procedures is expected to increase the accessibility and acceptance of biomarker tests in pediatric populations.

Market Restraints:

Despite the promising growth trajectory, several challenges may hinder the expansion of the pediatric cancer biomarkers market. High costs associated with biomarker discovery, validation, and testing technologies remain a significant barrier, particularly in low- and middle-income countries. Limited awareness about pediatric-specific biomarkers and a lack of standardized regulatory frameworks may further constrain market penetration. Moreover, the relatively small patient pool for individual pediatric cancer types makes large-scale clinical trials difficult, thereby slowing the approval and adoption of new biomarker tests.

Market Opportunities:

The pediatric cancer biomarkers market offers numerous opportunities for growth, particularly with the rising adoption of personalized medicine and targeted therapies. Continued investments in research and development are likely to yield new, clinically relevant biomarkers for rare and aggressive pediatric cancers. Strategic collaborations between diagnostic companies, research institutions, and healthcare providers can foster innovation and accelerate commercialization. Emerging markets across Asia-Pacific, Latin America, and the Middle East present untapped potential due to increasing healthcare investments and improving diagnostic infrastructure. Integration of artificial intelligence and big data analytics in biomarker research is also expected to revolutionize pediatric oncology diagnostics in the coming years.

Key Questions Answered in the Report:

What are the primary factors driving the global pediatric cancer biomarkers market's growth?
Which regions and cancer types are witnessing the highest demand for pediatric biomarkers?
How are advancements in genomics and molecular diagnostics shaping the market?
Who are the key players in the pediatric cancer biomarkers space, and what strategies are they implementing?
What are the emerging trends and projections for the pediatric cancer biomarkers market?

Competitive Intelligence and Business Strategy:

Leading companies in the pediatric cancer biomarkers market, including F. Hoffmann-La Roche Ltd, Abbott, QIAGEN, and Siemens Healthineers, are focusing on strategic partnerships, product innovation, and research collaborations to expand their market presence. These companies are investing heavily in the development of next-generation biomarker platforms, with an emphasis on non-invasive testing and high-throughput screening technologies. Efforts are being made to enhance clinical utility, streamline regulatory approvals, and broaden biomarker applications across multiple pediatric cancer types. Collaborations with hospitals and oncology centers, coupled with expansion into emerging markets, are key strategies to drive long-term growth.

Companies Covered in This Report:

F. Hoffmann-La Roche Ltd
Abbott
QIAGEN
Siemens Healthineers
Thermo Fisher Scientific
Beckman Coulter
Myriad Genetics
Agilent Technologies
Bio-Rad Laboratories
Randox Laboratories Ltd.
BIOMERIEUX
RayBiotech, Inc.
Others

Market Segmentation:

By Indication:

Leukemia
Neuroblastoma
CNS Tumors
Lymphoma
Others

By Biomarker:

Alpha-fetoprotein (AFP)
Neuron-specific Enolase (NSE)
CD19, CD20, CD22
ALK (Anaplastic Lymphoma Kinase)
Others

By End-use:

Hospitals
Diagnostic Laboratories
Oncology Centers
Research Institutions

By Region:

North America
Europe
East Asia
South Asia and Oceania
Latin America
Middle East and Africa

Product Code: PMRREP35328

1. Executive Summary

1.1. Global Pediatric Cancer Biomarkers Market Snapshot, 2025-2032
1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations

2. Market Overview

2.1. Market Scope and Definition
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Key Trends
2.3. Macro-economic Factors
- 2.3.1. Impact of Pediatric Oncology Infrastructure on Biomarker Testing Access
- 2.3.2. Trends in Pediatric Cancer Diagnostic Funding: Public vs. Private Sector
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

3.1. Product Adoption Analysis
3.2. Regulatory Landscape
3.3. Value Chain Analysis
3.4. PESTLE Analysis
3.5. Porter's Five Force Analysis

4. Pricing and Reimbursement Analysis, 2025A

4.1. Key Highlights
4.2. Overview of Pediatric Biomarker Testing Costs
4.3. Key Pediatric-specific Testing Cost Drivers
4.4. Reimbursement Policies for Pediatric Cancer Biomarkers by Region

5. Global Pediatric Cancer Biomarkers Market Outlook

5.1. Key Highlights
- 5.1.1. Market Volume (Units) Projections
- 5.1.2. Market Size (US$ Mn) and Y-o-Y Growth
- 5.1.3. Absolute $ Opportunity
5.2. Market Size (US$ Mn) and Volume (Units) Analysis and Forecast
- 5.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
- 5.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
5.3. Global Pediatric Cancer Biomarkers Market Outlook: Indication
- 5.3.1. Introduction / Key Findings
- 5.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis, By Indication, 2019-2024
- 5.3.3. Current Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, By Indication, 2025-2032
  - 5.3.3.1. Leukemia
  - 5.3.3.2. Neuroblastoma
  - 5.3.3.3. CNS Tumors
  - 5.3.3.4. Lymphoma
  - 5.3.3.5. Others
- 5.3.4. Market Attractiveness Analysis: Indication
5.4. Global Pediatric Cancer Biomarkers Market Outlook: Biomarker
- 5.4.1. Introduction / Key Findings
- 5.4.2. Historical Market Size (US$ Mn) Analysis, By Biomarker, 2019-2024
- 5.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
  - 5.4.3.1. Alpha-fetoprotein (AFP)
  - 5.4.3.2. Neuron-specific Enolase (NSE)
  - 5.4.3.3. CD19, CD20, CD22
  - 5.4.3.4. ALK (Anaplastic Lymphoma Kinase)
  - 5.4.3.5. Others
- 5.4.4. Market Attractiveness Analysis: Biomarker
5.5. Global Pediatric Cancer Biomarkers Market Outlook: End Use
- 5.5.1. Introduction / Key Findings
- 5.5.2. Historical Market Size (US$ Mn) Analysis, By End Use, 2019-2024
- 5.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By End Use, 2025-2032
  - 5.5.3.1. Hospital
  - 5.5.3.2. Diagnostic Laboratories
  - 5.5.3.3. Oncology Centers
  - 5.5.3.4. Research Institutions
- 5.5.4. Market Attractiveness Analysis: End Use

6. Global Pediatric Cancer Biomarkers Market Outlook: Region

6.1. Key Highlights
6.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis, By Region, 2019-2024
6.3. Current Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, By Region, 2025-2032
- 6.3.1. North America
- 6.3.2. Europe
- 6.3.3. East Asia
- 6.3.4. South Asia and Oceania
- 6.3.5. Latin America
- 6.3.6. Middle East & Africa
6.4. Market Attractiveness Analysis: Region

7. North America Pediatric Cancer Biomarkers Market Outlook

7.1. Key Highlights
7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 7.2.1. By Country
- 7.2.2. By Indication
- 7.2.3. By Biomarker
- 7.2.4. By End Use
7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 7.3.1. U.S.
- 7.3.2. Canada
7.4. Current Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, By Indication, 2025-2032
- 7.4.1. Leukemia
- 7.4.2. Neuroblastoma
- 7.4.3. CNS Tumors
- 7.4.4. Lymphoma
- 7.4.5. Others
7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
- 7.5.1.
  - 7.5.1.1. Alpha-fetoprotein (AFP)
  - 7.5.1.2. Neuron-specific Enolase (NSE)
  - 7.5.1.3. CD19, CD20, CD22
  - 7.5.1.4. ALK (Anaplastic Lymphoma Kinase)
  - 7.5.1.5. Others
- 7.5.2. Others
7.6. Current Market Size (US$ Mn) Analysis and Forecast, By End Use, 2025-2032
- 7.6.1. Hospital
- 7.6.2. Diagnostic Laboratories
- 7.6.3. Oncology Centers
- 7.6.4. Research Institutions
7.7. Market Attractiveness Analysis

8. Europe Pediatric Cancer Biomarkers Market Outlook

8.1. Key Highlights
8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 8.2.1. By Country
- 8.2.2. By Indication
- 8.2.3. By Biomarker
- 8.2.4. By End Use
8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 8.3.1. Germany
- 8.3.2. France
- 8.3.3. U.K.
- 8.3.4. Italy
- 8.3.5. Spain
- 8.3.6. Russia
- 8.3.7. Turkey
- 8.3.8. Rest of Europe
8.4. Current Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, By Indication, 2025-2032
- 8.4.1. Leukemia
- 8.4.2. Neuroblastoma
- 8.4.3. CNS Tumors
- 8.4.4. Lymphoma
- 8.4.5. Others
8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
- 8.5.1. Alpha-fetoprotein (AFP)
- 8.5.2. Neuron-specific Enolase (NSE)
- 8.5.3. CD19, CD20, CD22
- 8.5.4. ALK (Anaplastic Lymphoma Kinase)
- 8.5.5. Others
8.6. Current Market Size (US$ Mn) Analysis and Forecast, By End Use, 2025-2032
- 8.6.1. Hospital
- 8.6.2. Diagnostic Laboratories
- 8.6.3. Oncology Centers
- 8.6.4. Research Institutions
8.7. Market Attractiveness Analysis

9. East Asia Pediatric Cancer Biomarkers Market Outlook

9.1. Key Highlights
9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 9.2.1. By Country
- 9.2.2. By Indication
- 9.2.3. By Biomarker
- 9.2.4. By End Use
9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 9.3.1. China
- 9.3.2. Japan
- 9.3.3. South Korea
9.4. Current Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, By Indication, 2025-2032
- 9.4.1. Leukemia
- 9.4.2. Neuroblastoma
- 9.4.3. CNS Tumors
- 9.4.4. Lymphoma
- 9.4.5. Others
9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
- 9.5.1.
  - 9.5.1.1.
    - 9.5.1.1.1. Alpha-fetoprotein (AFP)
    - 9.5.1.1.2. Neuron-specific Enolase (NSE)
    - 9.5.1.1.3. CD19, CD20, CD22
    - 9.5.1.1.4. ALK (Anaplastic Lymphoma Kinase)
    - 9.5.1.1.5. Others
  - 9.5.1.2. Biopsy
- 9.5.2. Others
9.6. Current Market Size (US$ Mn) Analysis and Forecast, By End Use, 2025-2032
- 9.6.1. Hospital
- 9.6.2. Diagnostic Laboratories
- 9.6.3. Oncology Centers
- 9.6.4. Research Institutions
9.7. Market Attractiveness Analysis

10. South Asia & Oceania Pediatric Cancer Biomarkers Market Outlook

10.1. Key Highlights
10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 10.2.1. By Country
- 10.2.2. By Indication
- 10.2.3. By Biomarker
- 10.2.4. By End Use
10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 10.3.1. India
- 10.3.2. Southeast Asia
- 10.3.3. ANZ
- 10.3.4. Rest of South Asia & Oceania
10.4. Current Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, By Indication, 2025-2032
- 10.4.1. Leukemia
- 10.4.2. Neuroblastoma
- 10.4.3. CNS Tumors
- 10.4.4. Lymphoma
- 10.4.5. Others
10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
- 10.5.1. Alpha-fetoprotein (AFP)
- 10.5.2. Neuron-specific Enolase (NSE)
- 10.5.3. CD19, CD20, CD22
- 10.5.4. ALK (Anaplastic Lymphoma Kinase)
- 10.5.5. Others
10.6. Current Market Size (US$ Mn) Analysis and Forecast, By End Use, 2025-2032
- 10.6.1. Hospital
- 10.6.2. Diagnostic Laboratories
- 10.6.3. Oncology Centers
- 10.6.4. Research Institutions
10.7. Market Attractiveness Analysis

11. Latin America Pediatric Cancer Biomarkers Market Outlook

11.1. Key Highlights
11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 11.2.1. By Country
- 11.2.2. By Indication
- 11.2.3. By Biomarker
- 11.2.4. By End Use
11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 11.3.1. Brazil
- 11.3.2. Mexico
- 11.3.3. Rest of Latin America
11.4. Current Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, By Indication, 2025-2032
- 11.4.1. Leukemia
- 11.4.2. Neuroblastoma
- 11.4.3. CNS Tumors
- 11.4.4. Lymphoma
- 11.4.5. Others
11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
- 11.5.1. Alpha-fetoprotein (AFP)
- 11.5.2. Neuron-specific Enolase (NSE)
- 11.5.3. CD19, CD20, CD22
- 11.5.4. ALK (Anaplastic Lymphoma Kinase)
- 11.5.5. Others
11.6. Current Market Size (US$ Mn) Analysis and Forecast, By End Use, 2025-2032
- 11.6.1. Hospital
- 11.6.2. Diagnostic Laboratories
- 11.6.3. Oncology Centers
- 11.6.4. Research Institutions
11.7. Market Attractiveness Analysis

12. Middle East & Africa Pediatric Cancer Biomarkers Market Outlook

12.1. Key Highlights
12.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
- 12.2.1. By Country
- 12.2.2. By Indication
- 12.2.3. By Biomarker
- 12.2.4. By End Use
12.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
- 12.3.1. GCC Countries
- 12.3.2. Egypt
- 12.3.3. South Africa
- 12.3.4. Northern Africa
- 12.3.5. Rest of Middle East & Africa
12.4. Current Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, By Indication, 2025-2032
- 12.4.1. Leukemia
- 12.4.2. Neuroblastoma
- 12.4.3. CNS Tumors
- 12.4.4. Lymphoma
- 12.4.5. Others
12.5. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
- 12.5.1. Alpha-fetoprotein (AFP)
- 12.5.2. Neuron-specific Enolase (NSE)
- 12.5.3. CD19, CD20, CD22
- 12.5.4. ALK (Anaplastic Lymphoma Kinase)
- 12.5.5. Others
12.6. Current Market Size (US$ Mn) Analysis and Forecast, By End Use, 2025-2032
- 12.6.1. Hospital
- 12.6.2. Diagnostic Laboratories
- 12.6.3. Oncology Centers
- 12.6.4. Research Institutions
12.7. Market Attractiveness Analysis

13. Competition Landscape

13.1. Market Share Analysis, 2025
13.2. Market Structure
- 13.2.1. Competition Intensity Mapping By Market
- 13.2.2. Competition Dashboard
13.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 13.3.1. F. Hoffmann-La Roche Ltd
  - 13.3.1.1. Overview
  - 13.3.1.2. Segments and Indications
  - 13.3.1.3. Key Financials
  - 13.3.1.4. Market Developments
  - 13.3.1.5. Market Strategy
- 13.3.2. Abbott
- 13.3.3. QIAGEN
- 13.3.4. Siemens Healthineers
- 13.3.5. Thermo Fisher Scientific
- 13.3.6. Beckman Coulter
- 13.3.7. Myriad Genetics
- 13.3.8. Agilent Technologies
- 13.3.9. Bio-Rad Laboratories
- 13.3.10. Randox Laboratories Ltd.
- 13.3.11. BIOMERIEUX
- 13.3.12. RayBiotech, Inc.
- 13.3.13. Others

14. Appendix

14.1. Research Methodology
14.2. Research Assumptions
14.3. Acronyms and Abbreviations

Pediatric Cancer Biomarker Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032